Fierce Pharma June 27, 2022
The times are changing in the biopharma industry—and it’s happening fast. From 2019 to 2021, for example, total investment in biotechs nearly doubled, which helps explain why the average premium for purchasing biotech assets increased from 51% in 2018 to 71% last year.
Something else to consider: Over the last five years, biotechs accounted for 55% of the drugs on the market as opposed to just 30% from 2012 to 2016. Backed by investment power—biotechs have shown more willingness to bring their own assets to the market.
What does this all mean for the large cap biopharma sector?
It’s time for companies to reconsider their approach to M&A as the traditional methods of fostering growth are...
Today's Sponsors
Today's Sponsor